Published
November 13, 2023

CAESAR – Study 2

icon-benefit
Recruiting
HomeSubstudies
CAESAR – Study 2

Emergence of resistance is a major health care problem. When investigating the effect of different antibiotic treatment strategies it is important to obtain information on the emergence of resistant pathogens. At this time, it is unknown which treatment strategy has the least effect on the development of resistance. Cefazolin has more Gram-negative activity than flucloxacillin and may therefore lead to increased colonization with Enterobacterales producing extended-spectrum beta-lactamases (ESBL), but data are lacking.

This substudy is funded by the ZonMw Rational Pharmacotherapy program and is conducted in the Netherlands.

Coordinating investigator: Fleur Sinkeler, PharmD – Radboudumc, Nijmegen, the Netherlands

Principal investigator: Dr. Nynke Jager, PharmD – Radboudumc, Nijmegen, the Netherlands

What will the substudy involve – more information

One rectal swab is obtained at baseline, day 14 and day 42. In these swabs, the amount of resistant pathogens is assessed.

All S. aureus bacteraemia patients (≥ 18 years) treated with flucloxacillin or cefazolin (but who did not receive antibiotics within 90 days prior to collection of the index blood culture) included in the SNAP platform in the Netherlands are eligible for this substudy.

Risks and benefits of taking part in the sub study

The risk of taking a rectal swab is negligible, although you may feel reluctant to undergo the sampling. You may not benefit from this study, but it is possible that the results from this study will help us better understand if the different antibiotics used during treatment of S. aureus bacteremia result in the emergence of resistant pathogens. Research like this may also help us to improve the care and diagnosis of patients with kidney damage into the future.

Where will my sub study information be collected and stored?

All data obtained during this substudy be recorded pseudonymized, therefore the your identity cannot be deduced from the database. Only the local investigators will have access to this secured database and they will be the only ones able to add, change, or delete data

What if I withdraw from this sub study?

You can leave the study at any time for any reason if you wish to do so without any consequences. If you withdraw, we will keep any information we have collected about you up until you withdraw.

Sub Study Contacts

Name: Fleur Sinkeler

Email: CAESAR@radboudumc.nl

Substudies in Progress

SNAP Trial

CERT-SNAP

Combination Cefazolin with Ertapenem for methicillin-susceptible Staphylococcus aureus bacteremia.

icon-benefit
All Interested
icon-benefit
Substudy in Progress

DAPTO-SNAP

Daptomycin vs. Vancomycin for the Treatment of MRSA bacteremia

icon-benefit
All Interested
icon-benefit
Substudy in Progress

SABSI

Profiling the genetic and epigenetic determinants that predispose to severe manifestations of Staphylococcus aureus bacteremia

icon-benefit
All Interested
icon-benefit
Substudy in Progress
BACK TO TOP